Utama › Kanser Payudara Triple-Negatif › Kentucky
Kajian klinikal Kanser Payudara Triple-Negatif di Kentucky
6 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi di Kentucky.
Bandar di Kentucky
Teks kajian rasmi (Bahasa Inggeris)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044), Edgewood
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06393374Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Norton Healthcare, Inc., Louisville
- Mercy Health, Paducah
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT05846789Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT05005403The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Baptist Health Clinical Research, Elizabethtown
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Apr 2022 · NCT05037825Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.